Q-omics provides the consensus-scored NOXO1 profile across patient tissues and cancer cell-line models. NOXO1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NOXO1 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, NOXO1 RNA expression shows 6,631 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight UCEC, COAD, and READ as cancer lineages where NOXO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOXO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOXO1 survival associations across molecular data types. NOXO1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOXO1 RNA expression–survival associations across cancer types. High NOXO1 expression shows unfavorable associations in MESO, LIHC, LUAD and CHOL, but favorable associations in UCEC and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for NOXO1 RNA expression.
This table summarizes NOXO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for NOXO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOXO1 shows higher tumor expression in COAD. The COAD box plot shows higher NOXO1 RNA expression in tumor versus normal tissue (log2 FC = +0.074, t-test p = .004).
This table shows molecular features associated with NOXO1 in patient tissues and cancer cell lines. In patient samples, NOXO1 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set. In cancer cell lines, NOXO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
